CPHI’s Post

📣 Hello LinkedIn community! 📣 I’m reaching out to tap into your collective wisdom and gather your insights. Your opinions, comments, and experiences are incredibly valuable, and I believe we can learn a lot from the discussion we create together. Recently, I’ve been thinking about networking events within the European #pharma industry. Of course, #EuroPLX is well-known to many of us (which edition would you recommend for 2025 – Vienna or Cascais, by the way?). And then there's the upcoming #CPhI – can you believe it's less than three months away? But I’m curious – are there other European events or considerations we should be aware of, especially when working with #generics? Perhaps there are hidden gems or lesser-known conferences that have proven valuable. I’d love to hear your thoughts, tips, and stories. Whether it's about a fantastic event you've attended, a networking tip that's served you well, or anything else related to pharma networking, please share! Looking forward to your comments and learning from all of you! #PharmaIndustry #Networking #PharmaEvents #Pharmaceuticals #Healthcare #LifeSciences #PharmaNetworking #PharmaConferences #PharmaBusiness #PharmaMarketing #PharmaCommunity

I was pleased to share my thoughts on how biotech and pharma can become an early innovation partner of choice during a panel at #BIO2024 alongside Helena Chaye, CEO of our partner @KaliVir Immunotherapeutics, Olga Granaturova, President of PriveBio, Anna Chen, Principal, Frazier Life Sciences and David Kane, Arc Bio Communications, an IQVIA business. For me, three points stood out:    Strategic fit is all important, regardless of asset stage. It is the foundation for a successful partnership.   Communicate the whole value proposition. Alongside data, value can be demonstrated through people, advisors and scientific talent, unique capabilities or a differentiated asset strategy. A well-considered vision for the future is also key.   It’s never too early to start a conversation. The strongest partnerships are underpinned by mutual understanding and respectful, ongoing communication.    At @Astellas Pharma, innovation partnerships play a critical role in accelerating our progress in novel modalities, as we strive to deliver transformative VALUE to patients. Learn more here: https://lnkd.in/dd8tRfgB    #ScienceFirstForPatients #ChangingTomorrow 

FAIR isn't just about accessibility—it's about empowerment. Making data and analytics Findable, Accessible, Interoperable, and Reusable (FAIR) is important beyond academia, it’s also crucial in the biopharmaceutical industry. FAIR provides a foundation to advance knowledge within organizations and democratize access to insights. Dr. Jack DiGiovanna, CSO at Velsera, shared his insights on how embracing FAIR principles for data and analytics can help cross the chasm between basic research and novel therapeutics becoming standard of care during Bio-IT World 2024 earlier this month. FAIRness isn't without its challenges, especially when the principles are applied also to analytics. Time remains a powerful challenger, especially as the drug development life cycle with the standard turnover or reorganizations within the industry. Jack highlighted the importance of global standards, how they have been successfully applied, and where analytical platforms can serve as the bedrock of this transformative movement. Jack discussed how current platforms, especially in the NIH space, are paving the way for FAIR data and analysis; discussed key areas for future development; and highlighted where continuing support will be most impactful. Build a future where data isn't just collected—it's connected, shared, and utilized for meaningful impact with Velsera today! Make your analytics sharable, interpretable, and able to be validated. Contact us to learn more: https://lnkd.in/df3EP_2g #FAIRData #ResearchImpact #DataScience #Innovation

⬇ 𝗗𝗶𝘃𝗲 𝗶𝗻𝘁𝗼 𝘁𝗵𝗲 𝗥𝗲𝘂𝘁𝗲𝗿𝘀 𝗣𝗵𝗮𝗿𝗺𝗮 𝟮𝟬𝟮𝟰 𝗶𝗻𝘀𝗶𝗴𝗵𝘁𝘀 Were you at Reuters Pharma 2024 in Barcelona? Check out our 𝐕𝐨𝐢𝐜𝐞𝐬 𝐚𝐧𝐝 𝐓𝐨𝐩𝐢𝐜𝐬 𝐫𝐞𝐩𝐨𝐫𝐭 where we gathered curious insights and key takeaways. Here's what you can find: ⚡ leading industry figures, offering an in-depth look at their views and initiatives ⚡ most discussed topics at the conference, providing a clear picture of current trends and future directions ⚡a detailed breakdown of the most buzz-generating discussions https://lnkd.in/dBR8sHzc

🗓️ Mark your calendar for Jan. 18 at 11 a.m. ET! Join us for our FREE monthly Journal Club featuring the following industry experts: ▪️Rinol Alaj, Regeneron ▪️Amy Bertha, Bayer ▪️Imein Bousnina, Genentech ▪️Megan Doyle, Amgen ▪️Danielle Friend, Johnson & Johnson ▪️Lauren Oliva, Biogen ▪️Sarah Valentine, DiMe This discussion will center on a critical topic: Incorporating digitally derived endpoints within clinical development programs by leveraging prior work. 📰 To gain a deeper understanding of this topic, consider reading the article we'll be discussing: https://lnkd.in/dgEgjxvx In the manuscript, the authors discuss how to incorporate a #digital health technology and digitally derived endpoint within a #clinical development program, and how to leverage prior work to demonstrate they are fit for purpose to support a new drug marketing application. 🔗 Register and be part of this important discussion: https://lnkd.in/dkEBpMfd

After attending the recent Reuters Events Pharma USA 2024, which brought together leaders from the top 50 pharmaceutical companies, I've distilled the top 5 insights that stand out for their broad relevance to everyone in our industry (and if you were at PHARMA USA 2024, I’d love to hear your key takeaways). This event highlighted the need for visionary leadership and clear, actionable strategies to navigate the healthcare landscape—and amidst the backdrop of these discussions, a recurring question from many of you was: "When can we expect news on your next endeavor?" The sheer volume of these inquiries has been both humbling and a clear indicator that the time for my next big step is now. Each question about my future plans served as a reminder of the trust and expectations many of you have in my ability to contribute meaningfully as a partner and to our industry—for which I'm incredibly grateful. In response, I'm announcing the launch of my consulting firm for life sciences, Strategic Advisory for Leading Therapeutics Innovation Inc. (SALTI). The firm aims to provide clear guidance and actionable solutions toward "Advancing Medicine, Transforming Lives." And I'm excited to share more as we'll delve into the firm's founding purpose, articulate our vision, and outline our mission. Join us for the Full Launch Event: 🗓 Mark your calendar for May 1, 2024, at 10:00 a.m. ET. 📍 Broadcasting from our New York City office. Watch online at https://salti.co/. I invite everyone, whether you attended PHARMA USA 2024 or have insights to share, to join us in this important step forward. #REpharmaUSA #PharmaceuticalIndustry #HealthcareTransformation

How can we strengthen the ROI of incorporating digital biomarkers in drug development trials and accelerate its adoption… looking forward to hearing the sessions today and sharing the insights! #DigitalBiomarkersSummit #medidata #clinicalinnovation

Save the date: Swiss Biotech Day 2024 April 22-23, 2024 | Basel, Switzerland Join us at the Swiss Biotech Day, the premier biotechnology conference in Europe that brings together professionals from the global life sciences community. The conference offers international biotech delegations the opportunity to promote cross-border investments, public-private partnerships, research and development collaborations, and talent exchanges. You can set up a meeting with Erich Cavicchiolo, our Business Development Manager. Please contact us now to discuss your requirements. Join us in Basel on April 22-23, 2024, and make the most of the opportunity to connect with professionals from the global life sciences community. https://lnkd.in/d8gWk--X #swissbiotechday #swissbiotechday2024 #biotechnology #clinicalresearch #healthcaredata #healthcareit #healthcaresoftware #data #healthcare #pharmaceuticals #digitalhealthcare #pharmaceuticaltechnology #clinicalresearch #clinicaltrials #digitalhealth #healthtechnology #healthtech #clinicalresearch #clinical #cro #clinicaldata #clinicaltrialmanagement #clinicalstudies #clinicaldataplatforms #remotehealthcare #remotehealth #clinicaloperations #clinicaldevelopment #clinicaloperations #clinicaldata #remotemonitoring #datamanagementplatform #datamanagement #pharma #lifescience #rwe #rwd #epro #sops #etmf #edc #sdv #edc #cra #rtsm #sae #uat #gcp #qa #ecoa #iwrs #esource #econsent

Commercial data + pharma = NEXT Pharma Summit 🎉 💊 🎤 🎓 The NEXT Pharma Summit is one of the big events of the year in our industry and of course, our colleague Marcus Locher is right in the middle of it. Who else is there and have you met Marcus yet? #pharma #nextpharmasummit #commercialdata #dataanalytics #dataenthusiasts

Excellent discussion about the General Pharma Legislation #GPL at Nordic Life Science Days, with SwedenBIO and European Medicines Agency. With Jessica Martinsson and Falk Ehmann, we talked about how this generational change for medicines will shape what biotechnology innovation looks like for patients and national ecosystems, sitting within changing global and financial landscape. How AI, big data and real world evidence finds its way to benefit patients, the significance of regulatory sandboxes for breakthrough medicines particularly in unmet medical needs #UMN, how to use incentives to protect Europe's previous innovation flow and the role of stakeholders (ministries, governments, MEPs...) in getting the GPL right, with a critical phase going on right now in Brussels. It is critical for biotech innovators to be part of this discussion, form starts up through to global companies as they will be the ones travelling through the pipeline to patients and hold the shape of our future healthcare in their portfolios. Thanks to the great interventions from BioArctic (Gunilla Osswald), AstraZeneca (Pernilla Isberg), Janet Hoogstraate and Malin Eklund. EuropaBio - the European Association for Bioindustries